Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Recruiting 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 6CNS 6NET 5Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 40Gastro-enteropancreatic neuroendocrine tumor 8Paraganglioma 5Pheochromocytoma 4Neoplasms 2Carcinoma, Neuroendocrine 2Carcinoid Tumor 2Stomach Neoplasms 1Somatostatin Receptor-positive Neuroendocrine Tumor 1Sarcoma, Synovial 1Recurrence 1Pancreatic Neoplasms 1Pancreatic Diseases 1Osteosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Medulloblastoma 1Intestinal Neoplasms 1Intestinal Diseases 1Hypertension 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1

Interventions

lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 33-Iodobenzylguanidine 3Magnetic Resonance Spectroscopy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1olaparib 1fludarabine phosphate 1copper dotatate CU-64 1cabozantinib 1atezolizumab 1Specimen Handling 1Lutetium-177 1Lutetium 1Iodine-131 1Interleukin-13 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Cyclophosphamide 1Biopsy 190Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)- 13-fluorobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Paraganglioma × lutetium Lu 177 dotatate × NET × Clear all
NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
130 enrolled
CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT06607692 2026-04-14

LUPARPED

Fundación de investigación HM

Phase 1/2 Recruiting
25 enrolled
CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

University of Iowa

Phase 1/2 Withdrawn
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04029428 2020-04-01

POLNETS_PRRT

University of Warmia and Mazury

Phase 2 Unknown
150 enrolled
CNSEndocrineNET

Paraganglioma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡